The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
Open accessAbstract
Acinetobacter baumannii (A. baumannii) is undoubtedly one of the most successful pathogens in the modern healthcare system. With invasive procedures, antibiotic use and immunocompromised hosts increasing in recent years, A. baumannii has become endemic in hospitals due to its versatile genetic machinery, which allows it to quickly evolve resistance factors, and to its remarkable ability to tolerate harsh environments. Infections and outbreaks caused by multidrug-resistant A. baumannii (MDRAB) are prevalent and have been reported worldwide over the past twenty or more years. To address this problem effectively, knowledge of species identification, typing methods, clinical manifestations, risk factors, and virulence factors is essential. The global epidemiology of MDRAB is monitored by persistent surveillance programs. Because few effective antibiotics are available, clinicians often face serious challenges when treating patients with MDRAB. Therefore, a deep understanding of the resistance mechanisms used by MDRAB can shed light on two possible strategies to combat the dissemination of antimicrobial resistance: stringent infection control and antibiotic treatments, of which colistin-based combination therapy is the mainstream strategy. However, due to the current unsatisfying therapeutic outcomes, there is a great need to develop and evaluate the efficacy of new antibiotics and to understand the role of other potential alternatives, such as antimicrobial peptides, in the treatment of MDRAB infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
An intron binding protein is required for transformation ability of p53
Beenken, S. W., Karsenty, G., Raycroft, L., & Lozano, G. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.17.4747 · Cited by 45
Genetic Features of CTX-M-15-Producing Acinetobacter baumannii from Haiti
Potron, A., Munoz-Price, L. S., Nordmann, P., Cleary, T., & Poirel, L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05124-11 · Cited by 44
Mosqueda, N., Espinal, P., Cosgaya, C., Viota, S., Plasensia, V., Álvarez-Lerma, F., Montero, M., Gómez, J., Horcajada, J. P., Vilà, J., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-13 · Cited by 42
Ruzin, A. V., Immermann, F. W., & Bradford, P. A. (2010) · Microbial Drug Resistance · doi:10.1089/mdr.2009.0131 · Cited by 41
Moland, E. S., Craft, D. W., Chong, Y., Kim, S.-Y., Hachmeister, L., Sayed, S. D., & Thomson, K. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01581-07 · Cited by 41
Fernando, D. M., & Kumar, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr519 · Cited by 40
Bakour, S., Alsharapy, S. A., Touati, A., & Rolain, J. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2014.0018 · Cited by 39
Morfín‐Otero, R., & Dowzicky, M. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.028 · Cited by 39
Principe, L., Capone, A., Mazzarelli, A., et al. (2013) · Microbial Drug Resistance · doi:10.1089/mdr.2012.0250 · Cited by 38
IS CR2 , Another Vehicle for bla VEB Gene Acquisition
Poirel, L., Mugnier, P. D., Toleman, M. A., Walsh, T. R., Rapoport, M., Petroni, A., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00414-09 · Cited by 38
Shelburne, S. A., Singh, K. V., White, A. C., Byrne, L., Carmer, A., Austin, C., Graviss, E. A., Stager, C. E., Murray, B. E., & Atmar, R. L. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01459-07 · Cited by 35
Li, Y., Guo, Q., Wang, P., Zhu, D., Ye, X., Wu, S., & Wang, M. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.04.005 · Cited by 29
Liao, C., Kung, H., Hsu, G., Lu, P., Liu, Y.-C., Chen, C., Lee, C.-M., Sun, W., Jang, T.-N., Chiang, P.-C., et al. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70027-x · Cited by 25
Hong, S. B., Shin, K. S., Ha, J., & Han, K. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.055384-0 · Cited by 19
Fillaux, J., Dubouix, A., Conil, J., Laguerre, J., & Marty, N. (2006) · Infection Control and Hospital Epidemiology · doi:10.1086/507082 · Cited by 17
Cited by
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Acinetobacter baumannii Biofilm Formation and Its Role in Disease Pathogenesis: A Review
Gedefie, A., Demsiss, W., Belete, M. A., Kassa, Y., Tesfaye, M., Tilahun, M., Bisetegn, H., & Sahle, Z. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s332051 · Cited by 351
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
Nguyen, M., & Joshi, S. G. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15130 · Cited by 259
Ma, S., Shungin, D., Mallick, H., Schirmer, M., Nguyen, L. H., Kolde, R., Franzosa, E., Vlamakis, H., Xavier, R., & Huttenhower, C. (2022) · Genome biology · doi:10.1186/s13059-022-02753-4 · Cited by 164
Metadata
- Authors
- Lin, M.-F.
- Venue
- World Journal of Clinical Cases
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2014
- Volume
- 2
- Issue
- 12
- Pages
- 787
- ISSN
- 2307-8960 (ISSN-L)
- OpenAlex
- W2047365652
- Cited by
- 357
- References
- 215
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.